

Listing of Plenary, Oral and Poster Presentations of the 28th Annual Meeting of the American Brachytherapy Society

PLENARY PAPERS
Monday April 30, 2007
1:30 PM–2:30 PM

PL-1 Presentation Time: 1:30 PM

Partial breast irradiation using multicatheter interstitial brachytherapy for early breast cancer – results of the German-Austrian phase II study
Vratislav Strnad, M.D. Radiation Oncology, University Hospital Erlangen, Erlangen, Germany.

PL-2 Presentation Time: 1:45 PM

A comparison of overall survival between patients with low and intermediate-risk prostate cancer treated with brachytherapy, external beam radiotherapy, or radical prostatectomy
Jay P Ciezki, M.D. Radiation Oncology, Cleveland Clinic, Cleveland, OH.

PL-3 Presentation Time: 2:00 PM

3D image-guided HDR brachytherapy in locally advanced cervix cancer – comparison of intracavitary and interstitial treatment
Subrata Saha, M.D. Radiotherapy, Medical College Hospital, Calcutta, Calcutta, West Bengal, India.

PL-4 Presentation Time: 2:15 PM

Interstitial prostate implant brachytherapy using an automated, 3-D greedy heuristic optimization and I-125 directional sources
Vibha Chaswal, MS Medical Physics, Nuclear Engineering and Engineering Physics, University of Wisconsin, Madison, WI.

PROSTATE PAPER SESSION
Sunday April 29, 2007
9:00 AM–10:00 AM

OR-1 Presentation Time: 9:00 AM

Clinical outcomes of a phase II, multi-institutional Cesium-131 permanent prostate brachytherapy trial
Bradley R Prestidge, M.D.^{1,2} ¹Texas Cancer Clinic, San Antonio, TX; ²Radiological Sciences, UTHSCSA, San Antonio, TX.

OR-2 Presentation Time: 9:10 AM

Permanent prostate brachytherapy for high-risk prostate cancer
Gregory S Merrick, M.D. Schiffler Cancer Center, Wheeling Hospital, Wheeling, WV.

OR-3 Presentation Time: 9:20 AM

A comparison of biochemical relapse-free survival in patients with intermediate-risk prostate cancer treated with radical prostatectomy, external beam radiotherapy, or permanent seed implantation
Andrew D Vassil, M.D. Radiation Oncology, Cleveland Clinic, Cleveland, OH.

OR-4 Presentation Time: 9:30 AM

Permanent ¹²⁵I prostate brachytherapy performed in the community setting: validation of the benefit of postimplant CT dosimetry and the prostate D-90 as a predictor of 5-YEAR bNED outcome
David Linstadt, M.D. Radiation Oncology, RASMG, Auburn, CA.

OR-5 Presentation Time: 9:40 AM

Prostatic acid phosphatase predicts cancer-specific survival after Palladium-103 brachytherapy for prostate cancer
L Christine Fang, M.D. Radiation Oncology, University of Washington, Seattle, WA.

OR-6 Presentation Time: 9:50 AM

Cesium¹³¹ prostate brachytherapy: an early experience
Brian J Moran, M.D. Chicago Prostate Cancer Center, Westmont, IL.

BREAST PAPER SESSION
Sunday April 29, 2007
1:45 PM–2:30 PM

OR-7 Presentation Time: 1:45 PM

Stereotactic breast brachytherapy applied peripherally using a compression applicator and HDR ¹⁹²Ir
Mark J Rivard, Ph.D. Radiation Oncology, Tufts-New England Medical Center, Boston, MA.

OR-8 Presentation Time: 1:54 PM

Dosimetric comparison of three radiation sources used in balloon-based breast brachytherapy
John J Munro, III, Ph.D. SPECMed LLC, St. Rose, LA.

OR-9 Presentation Time: 2:03 PM

Accelerated partial breast irradiation therapy with MammoSite balloon catheter for early breast cancer: A review of patients treated at a large community hospital

Sudha B Mahalingam, M.D. Radiation Therapy, Bethesda North Hospital, Cincinnati, OH.

OR-10 Presentation Time: 2:12 PM

A novel hybrid method of breast brachytherapy: the best of both worlds

Charles W Hodge, M.D. Human Oncology, University of Wisconsin, Madison, WI.

OR-11 Presentation Time: 2:21 PM

Factors affecting seroma formation in patients treated with MammoSite

Janice K Tomberlin, M.D. Radiation Oncology, Texas Oncology, Bedford, TX.

MISCELLANEOUS PAPER SESSION

Sunday April 29, 2007

2:30 PM–3:00 PM

OR-12 Presentation Time: 2:30 PM

Total eye plaque activity (u) as a prognostic factor of visual outcome of uveal melanoma patients treated with custom-made Nag Iodine-125 eye plaque

Moataz N El-Ghamry, M.D. Radiation Medicine, Ohio State University, Columbus, OH.

OR-13 Presentation Time: 2:40 PM

Penile brachytherapy: Results for 60 patients

Juanita M Crook, M.D. Radiation Oncology, Princess Margaret Hospital, Toronto, ON, Canada.

OR-14 Presentation Time: 2:50 PM

Patterns of care for brachytherapy in Europe: Results for 2002 and projects for 2007

Ferran Guedea, M.D., Ph.D. Radiation Oncology, Catalan Institute of Oncology, Barcelona, Spain.

GYN PAPER SESSION

Sunday April 29, 2007

4:30 PM–5:30 PM

OR-15 Presentation Time: 4:30 PM

MRI-based brachytherapy treatment planning for cervix cancer

Daniel Zwahlen, M.D. Radiation Medicine Program, Princess Margaret Hospital, Toronto, ON, Canada.

OR-16 Presentation Time: 4:40 PM

Adjuvant brachytherapy removes the survival disadvantage of local disease extension in FIGO IIIC endometrial cancer: A SEER registry analysis

Peter J Rossi, M.D. Radiation Oncology, Emory University School of Medicine, Atlanta, GA.

OR-17 Presentation Time: 4:50 PM

CT-based cervix HDR brachytherapy treatment planning: Is CT simulation necessary for each HDR insertion?

Melanie TM Davidson, Ph.D. London Regional Cancer Program, London Health Sciences Center, London, ON, Canada.

OR-18 Presentation Time: 5:00 PM

Dosimetric comparison of IMRT to HDR intracavitary brachytherapy for cervical cancer

Michael C Dobelbower, M.D., Ph.D. Radiation Oncology, University of Alabama, Birmingham, Birmingham, AL.

OR-19 Presentation Time: 5:10 PM

The sigmoid: An organ at risk

Beth A Erickson, M.D. Radiation Oncology, Medical College of Wisconsin, Milwaukee, WI.

OR-20 Presentation Time: 5:20 PM

The effect of raising bladder volume on dosimetry of organs at risk in high-dose-rate intracavitary and interstitial brachytherapy of carcinoma cervix

Bikramjit Chakrabarti, M.B.B.S. Radiotherapy, Calcutta Medical College, Calcutta, West Bengal, India.

PROSTATE PAPER SESSION

Monday April 30, 2007

8:00 AM–9:00 AM

OR-21 Presentation Time: 8:00 AM

Long-term outcome for high-dose-rate brachytherapy boost treatment of prostate cancer

Yasmin Hasan, M.D. Radiation Oncology, William Beaumont Hospital, Royal Oak, MI.

OR-22 Presentation Time: 8:10 AM

Interstitial high-dose-rate brachytherapy for early stage prostate cancer: A report of 193 cases

Rufus J Mark, M.D.^{1,2} ¹Radiation Oncology, Joe Arrington Cancer Center, Lubbock, TX; ²Radiation Oncology, Texas Tech University Medical Center, Lubbock, TX.

OR-23 Presentation Time: 8:20 AM

The role of needle trauma to the neurovascular bundle region and its impact on potency following high-dose-rate brachytherapy

Michel Ghilezan, M.D. Radiation Oncology, William Beaumont Hospital, Royal Oak, MI.

OR-24 Presentation Time: 8:30 AM

Interstitial hyperthermia during HDR brachytherapy monotherapy for treatment of early stage prostate cancer with benign prostate hyperplasia

Venita L Williams, M.D. Radiation Oncology, University of California, Irvine, Orange, CA.

Download English Version:

<https://daneshyari.com/en/article/3978133>

Download Persian Version:

<https://daneshyari.com/article/3978133>

[Daneshyari.com](https://daneshyari.com)